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Abstract 
Tumor heterogeneity is the major cause of failure in cancer prognosis and prediction. Accurately 
detecting heterogeneity for the development of biomarkers and the detection of the clones 
resistant to therapy is one of the main goals of contemporary medicine. Metastases belong to the 
natural history of cancer. The present review gives an overview on the origin of tumor 
heterogeneity. Recent progress has made it possible to isolate and characterize circulating tumor 
cells (CTCs), which are the drivers of the disease between the primary sites and metastatic foci. The 
most recent methods for characterizing CTCs are summarized and we discuss the power of CTC 
profiling for analyzing tumor heterogeneity in early and advanced diseases. 
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Introduction 
Anyone who has observed a tumor section 
under a microscope is familiar with the significant 
heterogeneity of the tumor mass. Within a single 
tumor mass, several foci with various, specific 
histological features can cohabit (Figure 1). In 
addition to their diverse morphology, cancer cells 
exhibit considerable heterogeneity in terms of genetic 
profile, gene expression, metabolic property, motility, 
proliferation and metastatic potential [1]. As proposed 
by S. Paget with the “seed and soil” theory, a 
symbiosis is established between cancer cells and 
their local micro-environment, defining the notion of 
tumor niche favorable for tumor growth [1]. Cancer 
cells regulate their environment by direct cellular 
contacts [1] or by secreting soluble extracellular 
vesicles [1]. In return, the micro-environment impacts 
the differentiation, proliferation and death of cancer 
cells, as well as contributing to a selection process 
leading to drug resistance, cell dormancy [1] and to an 
immune-tolerant environment [1]. Cancer cells are 
then functionally entangled with numerous other cell 
types (e.g. stromal cells, endothelial cells, immune 
infiltrate) that enrich the heterogeneous character of 
tumor tissues. Consequently, tumor heterogeneity is 
not a fixed state but should be considered as a 
dynamic ecosystem that evolves as the tumor pro-
gresses and is strongly modulated under therapeutic 
pressure. Tumor heterogeneity is subject to major 
spatial and temporal modulations that can impair 
sustained therapeutic response and drug sensitivity.  
The evolution in good clinical practices (e.g. 
needle biopsies) has recently led to a significant 
decrease in the amount of biological material avail-
able for molecular investigations. A biopsy cannot 
reflect and illustrate spatial tumor heterogeneity and 
should be considered as a partial photograph of the 
tumor mass at a given time. The follow-up of the 
dynamic process requires repeated sampling carried 
out using low invasive methods and should be as 









Repeated biopsies are ethically non-acceptable and 
sometimes unrealistic for high-risk localizations of 
metastatic foci (e.g. the spine). The establishment of 
metastatic disease is directly related to the migration 
of cancer cells called circulating tumor cells (CTCs) 
into the blood and/or lymphatic circulation, plus 
their ability to reach distant organs [1]. However, 
although CTCs are theoretically easily accessible, their 
low number makes it challenging to isolate and 
characterize them. The last decade has seen a surge in 
the new devices available for isolating CTCs, and 
specific downstream analysis workflows have been 
proposed in order to evaluate their biological value 
(e.g. therapeutic response, drug resistance, reflection 
of the tumor heterogeneity). The present review will 
give a brief overview of tumor heterogeneity: its 
origin, biological and clinical impacts and the 
methods for assessing it. We will put specific focus on 
the recent methods developed for isolating single cells 
and how these single cells can help to decipher this 
heterogeneity. We will also discuss how better 
characterization of single cells may orient future 
clinical decisions. 
Tumor heterogeneity: origins and 
enrichment 
Origin of cancer cell heterogeneity: from 
monoclonal to polyclonal disease 
Cancer is characterized by the development and 
growth of abnormal cell populations (e.g. mutations, 
altered proliferation and/or differentiation). As DNA 
is the only cell component that can accumulate and 
transmit changes throughout life, it has been accepted 
that the carcinogenesis process requires the pro-
gressive accumulation of multiple DNA modifications 
[2]. The current, generally-accepted model for 
carcinogenesis is the somatic mutation or clonal 
evolution theory (Table A) [3, 4]. Although it is the 
prevailing model for carcinogenesis, it has been 
challenged by several lines of evidence [1, 2, 5, 6]. The 
main alternative model focuses on the concept of 
asymmetric division initially observed in healthy 
tissue renewal [1, 2, 5, 6]. This process is defined as a 
biological process in which a single cell generates two 
daughter cells with two distinct destinies: one 
undifferentiated cell – a stem cell – expressing stem-
ness markers (e.g. Oct4, nano, sox2) and in charge of 
the self-tissue renewal, and one committed to a 
specific form of differentiation [14]. A similar process 
has been proposed in cancer leading to the 
maintenance of cancer-like “stem-cells” harboring the 
mutated driven gene and participating in the dynamic 
enrichment of the spatial and temporal heterogeneity 
of cancer cells [1,5,15,16]. Regardless of the 
carcinogenesis model, mutations in the tumor driven 
gene expressed by cells from pre-neoplastic lesions 
(e.g. TP53, Rb) lead to the formation of neoplastic foci 
characterized at the early stage by monoclonal 
expansions of mutated cells. This type of mutation 
results in genomic instabilities characterized by a high 
sensitivity to chromosome breakages and conse-
quently a new series of mutations, deletions, and 
amplifications [17] (Figure 2A). Random chromosome 
breakages and secondary genetic events clearly 
contribute to the development of cancer cells with a 
new genotype and phenotype, and then to the 
polyclonal expansion stage of the disease. Epigenetic 
modifications complete the framework of 
heterogeneity mapping. As revealed by genetically 
homogeneous cell lines, intercellular epigenetic 
alterations (e.g. DNA methylation, miRNA 
expression, etc) strengthen tumor heterogeneity and 
the drug response [5,18,19]. Genetically- and 
epigenetically-modified cells are prone to migrate 
from their primary site. In the natural history of 
cancer, the diffusion of cancer cells from a primary 
tumor to a secondary distant organ is frequently 
observed. Interestingly, several authors have 
demonstrated the migration of prostate cancer cells 
from metastastic foci to seed new, distant locations or 
pre-existing lesions, and consequently permanently 
enrich the heterogeneity of the tumor [20, 21]. Thus, 
the bidirectional seeding between different tumor 
sites plays a part in enriching tumor heterogeneity. 
 
Table A. Models of carcinogenesis. 
• The somatic mutation or clonal evolution theory is based on DNA 
changes in oncogenes and tumor-suppressor genes that lead to 
alterations in cell proliferation and/or cell-cycle arrest and/or cell 
differentiation and/or inhibition cell death. 
• The stem cell division theory for cancer suggests that Tumor-Initiating 
Cells (TICs) are the origin of cancer development. TICs are 
characterized by their capacity for self-renewal and play a part in the 
development of the heterogeneous lineages of cancer cells by 
accumulating successive asymmetric cell divisions. Similar to stem 
cells, TICs carry individual DNA from zygote to death and therefore 
hold the DNA long enough to accumulate the alterations required for 
carcinogenesis. 
 
Similarly to embryonic cells, cancer cells are not 
blocked in a defined state and adapt permanently 
their phenotype under the microenvironment and 
therapeutic pressure. Indeed, phenotypic and 
functional plasticity is a common mechanism 
observed during embryonic development [22]. 
Blastocyst cells are composed of various cell types 
including stem cells, lineage-committed progenitors 
and differentiated cells linked by hierarchical 
relationships that make possible the formation of all 
the organs of the future embryo/fetus and also the 
extra-embryonic annex from the pre-implantation 





step to the final gestation. All of these cells can switch 
between different cell states thanks to a high degree 
of plasticity. Similarly, cancer cells exhibit marked 
plasticity as illustrated by the epithelial-mesenchymal 
transition (EMT) in which cancer cells progressively 
acquire a mesenchymal phenotype and lose their 
epithelial properties, thus leading to the metastatic 
process. In the opposite direction, at the metastatic 
location, cancer cells undergo mesenchymal-epithelial 
transition (MET) and re-acquire their epithelial 
characteristics [23]. Inoculation into immunocompe-
tent mice of pure EpCAM+ or EpCAM- breast cancer 
cells, sorted by flow cytometry, led to the detection of 
mixed EpCAM+/EpCAM- cells in the blood stream 
after a couple of days. This simple experiment 
perfectly illustrates the extreme plasticity of cancer 
cells [24] (Figure 2B). The notion of plasticity should 
be extended to any subtle equilibrium making 
possible the functional orchestration of various cell 
populations. Recently, Franzetti et al. studied the 
impact of EWSR1/FLi1 expression on the functional 
behavior of Ewing sarcoma cells [25]. They observed 
that cancer cells fluctuated over time from low to high 
EWSR1/FLi1 expression in a reversible process, and 
the low expression phenotype was correlated with a 
metastatic profile (e.g. high propensity to migrate and 
invade). Both cell populations can co-exist in patient 
samples and EWSR1/FLi1Low contribute to the 
maintenance of tumor growth based on ESWR1/FL1 
re-expression. Their manuscript illustrates a new 
model of phenotypic plasticity and gives evidence of 
the functional impact of this dynamic phenotypic 
fluctuation associated with a dominant oncogene. 
However, the therapeutic pressure plays a 
significant role in the selective amplification of tumor 
heterogeneity and contributes to emergence of 
specific dominant clones driving the tumor hetero-
geneity [26]. A tumor mass is composed of a panel of 
cancer cells with sensitivity or innate resistance to a 
specific drug or specific therapeutic intervention [29] 
(Figure 2). Drug resistant clones are then preferen-
tially chosen and in turn selectively modify the tissue 
heterogeneity. Therapeutic selective pressure is also 
responsible for acquired resistance mechanisms 
resulting in the dynamic emergence of new cancer cell 
clones leading to dynamic heterogeneity. The notion 
of drug resistance is also related to persister cells 
observed in cancer and in micro-organisms [5]. 
Persisters are low proliferating cells with a stem-like 
profile and immune tolerant activities. Overall, the 
literature demonstrates that tumor heterogeneity 
becomes an obstacle to determining the appropriate 
therapeutics in oncology because of the temporal 
instability of tumor tissue organization. The dynamic 
evolution of dominant clones and persister cells fuel 
the tumor heterogeneity which is enriched by a 
heterogeneous local micro-environment.  
 
 
Figure 1. Typical microscopic observation of tumor heterogeneity. Osteosarcoma is a rare form of bone cancer mainly affecting adolescents and young 
adults. Osteosarcoma is a perfect illustration of highly heterogeneous tumors with multiple, diverse histological areas in a same tumor mass including osteoid, 
hypervascularized, proliferative and necrotic foci. In addition, associated lung metastases exhibit a histological morphology different from the primary tumor 
highlighting the contribution and effect played by the pressure of the local micro-environment on tumor heterogeneity. 






Figure 2. Tumor models and tissue heterogeneity. A. From a pre-neoplastic lesion to the development of metastases, the tumor tissue will undergo a marked 
cellular evolution leading to polyclonal disease. Tumor driven genes appearing in determined normal cells will be responsible for chromosomal instability with 
numerous chromosome breakages (fusions, deletions, etc) concomitant to secondary genetic and epigenetic events. From the detection of the first oncogenic event, 
new clones will be formed and will enrich the heterogeneity of the tumor. The pressure of the local micro-environment and/or the therapeutic pressure will enrich 
the tumor mass in dominant/resistant clones, which will leave the primary tumors to spread to distant organs. Tumor heterogeneity is a property of cancers sustained 
and amplified by the reseeding of cancer cells from one site to distant foci. B. Several models of tumor development have been proposed and may coexist 
simultaneously in a single tumor mass. Three main models can be described: i) clonal evolution of an initial cancer cell in which subsequent genomic abnormalities 
occur will lead progressively (in a linear manner) to the emergence of new clones; ii) the various oncogenic events can also lead to the establishment of multiple 
subclones with common ancestors; this type of model is called the “branched model”; iii) more recently, both models have been completed by the “plasticity model” 
directly related to the plasticity property of cancer cells. One cancer cell can evolve between two phenotypic states, A/B, linked to various functional states explaining 
the co-existence and equilibrium of a mixed population expressing a large panel of fusion genes or/and cluster of differentiation and contributing to the polyclonal 
expansion and heterogeneity of the tumors. This type of mechanism increases the chance of survival for a cancer cell by upmodulating its adaptability to the 
micro-environment in a permanent manner.  
 
Heterogeneity of the tumor 
micro-environment: the functional 
relationship of tumor heterogeneity  
As described above, from a clonal disease, the 
successive mutations in tumor cells play a part in 
temporal heterogeneity and the establishment of a 
very complex polyclonal oncogenic disease. In 
addition to the heterogeneous populations of 





neoplastic cells, tumor bulk is composed of 
non-neoplastic resident cells, the extracellular matrix 
[7-10], fibroblasts (called cancer-associated fibroblast) 
[7-10], blood vessels [7-10] and immune cells [7-10] 
that together form the tumor micro-environment 
(TME) (Figure 3). MALDI imaging mass spectrometry 
makes it possible to visualize tumor heterogeneity at 
the protein level [7-10]. Extracellular matrix is a key 
factor related to metastasis efficiency, controlling 
collective cell invasiveness [7-10]. This observation is 
related to the diversity of cancer-associated fibroblasts 
(CAF) [7-10]. Indeed, Costa et al. identified four 
subsets of CAF in breast cancer with specific distinct 
functional properties. In triple negative breast 
cancers, one of them, called CAF-S1, promotes an 
immune tolerant environment and stimulates T 
lymphocytes toward an immunosuppressive pheno-
type (CD25high FOXP3high). The second, called CAF-S4, 
increases the T cells’ regulatory property to inhibit T 
effector proliferation. Consequently, the local 
accumulation of CAF-S1 then contributes to tumor 
heterogeneity and to local immunosuppression 
observed in triple negative breast cancers. Such 
immunoregulation is tightly controlled by the 
production of local immunocytokinic signals leading 
to a balance between inflammatory and immuno-
suppressive effectors [7-10]. The functional impact of 
CAF on local tumor immunity is directly linked to the 
spatial and temporal heterogeneity of T lymphocytes 
and macrophages observed in numerous types of 
cancer [31-33[7-10]. Interestingly, resident lympho-
cytes seem pre-adapted to specific tissues and can 
adapt to wherever they migrate [34[7-10]. As a 
consequence of local immune regulation, endothelial 
cells exhibit several phenotypic features and lead to 
the formation of specific tumor vasculature [7-10].  
Interestingly, Hamilton et al. revealed that CTCs are 
competent to modulate tumor associated macro-
phages in order to increase invasiveness of cancer 
cells, angiogenesis and immunosuppression [7-10]. 
The quality (e.g. topographic localisation) and 
quantity of the immune infltrates into tumor tissues 
have strong impacts on patients' clinical outcomes. 
New technologies such as multispectral imaging will 
allow to obtain a precise analysis of these infiltrates 
and may lead to a better patient stratification [7-10]. 
All components of the tumor microenvironment then 
play a part in generating more tumor variability, as 
well as being highly heterogeneous and crucial for 
determining the development of cancer [7-10]. After 
the tumor excision and the initiation of the therapy, 
the key challenging question remains the follow up of 
the tumor heterogeneity in absence of tumor tissue 
access? Do CTCs reflect the tumor heterogeneity?  
 
 
Figure 3. Spatial immunological heterogeneity of tumor tissue. Illustration of the heterogeneity of immune infiltrates associated with human osteosarcoma 
(cohort previously published in [137]). Numerous immune cell subtypes invade osteosarcoma tissues during tumor development. Interestingly, their spatial 
distribution shows a high heterogeneity across the tumor tissue, with CD3+ T lymphocytes organized in a diffuse infiltrate as well as small clusters. The localization 
of CD8+ T cells is diffuse with one area without any infiltrated cells. Macrophages exhibit similar distribution to CD3 and the number of CD20+ B lymphocytes is 
relatively low but B cells are sometimes organized in pseudo-nodules. CD117+ mastocytes are also observed as diffuse infiltrate in a specific area.  





The characterization of circulating tumor cells 
for predicting tumor heterogeneity 
Tumor heterogeneity has challenged the 
potential benefits of precision medicine. Current 
methods used to analyze tumor masses and further 
therapeutic design are based on a global overview of 
the characteristics of cancer tissues, corresponding to 
an average picture of all the tumor clones and their 
micro-environment without considering their diver-
sity [11]. This variability limits the prognosis and 
predictive power of a biomarker. Moreover, 
differences in the evolution of tumor cells and 
micro-environments at the metastatic sites question 
the utility of the biomarkers previously identified in 
the primary tumor for treating metastatic disease [12, 
13]]. Monitoring changes in cell populations during 
disease progression and treatment will improve both 
cancer diagnosis and therapeutic design. Current 
protocols to check the consistency of the biomarkers, 
establish diagnoses and define treatment are based on 
very small biopsies (e.g. needle biopsies) of the 
primary tumor and metastatic sites. The main 
limitation is that most metastases are difficult to 
access, and biopsies are invasive, inconvenient, costly 
and do not make possible longitudinal follow-up of 
tumor heterogeneity. To overcome these problems, 
detecting and characterizing heterogeneity in CTCs 
could be a good alternative and opportunity.  
CTC characteristics as a snapshot of tumor 
heterogeneity 
In the last decade, numerous clinical studies 
revealed the link between CTC numbers and 
metastatic prognosis [49, 50]. Similarly, the 
phenotypic properties of CTCs can be related to 
overall patient survival [51]. In the most recent 
meta-analyses published, the authors found a 
correlation between CTC count and clinical 
progression. Recently, by combining more than 20 
published studies, CTC count was shown to be an 
independent and quantitative prognostic factor in 
patients suffering from early breast cancer [52]. At the 
protein level, there are some discrepancies depending 
on the series analyzed. In breast cancer for instance, 
HER2 expression between initial tumor tissues and 
corresponding CTCs are contradictory, with a 
concordance of around 90% for some of them [52,53], 
inconsistency for others [54] or fluctuating variations 
in the course of the disease [55]. Similar to EpCAM, 
the high plasticity of cancer cells results in variations 
in HER2 expression and reflects a snapshot of tumor 
heterogeneity at a specific time point. However, 
several studies support the idea that cellular 
heterogeneity in CTCs reflects the spectrum of 
mutations in the primary tumor and metastatic 
lesions. Mohamed Suhaimi et al. detected a high 
concordant mutation list in CTCs and tissues (e.g. 
KRAS and BRAF markers), predicting the outcome of 
anti-EGFR therapy in colorectal cancer patients [14]. 
Bingham et al. showed that CTCs were representative 
of the entire spectrum of mutations present in the 
primary tumor and distal metastases for patients with 
breast cancer. Their findings suggested the utility of 
CTCs for identifying targetable mutations and for 
being used as a biomarker to reveal cell populations 
sensitive to current or previous therapies [15].  
Despite these promising results, the existence of 
heterogeneity in the CTC compartment has been 
demonstrated, as shown by Pestrin et al., who 
observed variability in the mutational status of the 
PIK3CA gene in breast cancer patients. The PIK3CA 
mutation profile has prognostic significance and is 
potentially predictive for the response to agents 
targeting the PI3K pathway 8 Similarly, Pailler et al. 
observed considerable heterogeneity in ROS1-gene 
abnormalities in CTCs from non-small cell lung 
cancer (NSCLC), which could explain the mechanism 
by which tumor cells can escape sensitivity to 
ROS1-inhibitor therapy [16]. Furthermore, it has also 
been demonstrated that CTC profiles evolve as the 
disease progresses, illustrating the temporal 
heterogeneity of cancer diseases. Tsao et al. then 
mapped the phenotypic evolution of melanoma CTCs 
and detected the presence of drug-resistant clones 
harboring different molecular signatures of potential 
clinical value [17]. The discordance observed between 
CTCs and tumor heterogeneity may be explained by 
the dynamic heterogeneity of the CTCs [61, 62]. 
Primary tumors as well as metastatic foci are 
permanently reorganized, resulting dynamically in 
the differentiation and release of new cancer cell 
clones into the bloodstream, explaining the partial 
genomic overlap of CTCs and tumor foci at a specific 
time point. Consequently, even CTCs cannot fully 
reflect tumor heterogeneity: they are the mirror and 
snapshot of the disease’s progression as well as the 
clonal evolution of the tumor foci. Overall, the data 
currently available has pointed out the major 
advantages of CTC investigation at the single cell 
level, possibly representing the most accurate strategy 
for determining the temporal heterogeneity of the 
disease. 
Single CTC analysis could effectively reveal the 
high heterogeneity, stochastic changes, and driver 
mutations in cancer cell populations in order to detect 
drug resistance, and develop new personalized 
therapeutic strategies as well as their use as prediction 
markers. De Luca et al. validated a protocol to assess 
the clonal evolution of metastatic breast cancer, based 
on single CTC analysis by next generation sequencing 





(NGS), suitable for the development of new 
therapeutic strategies in precision medicine [18]. 
Miyamoto et al. analyzed single-cell RNA-sequencing 
(RNA-Seq) profiles in prostate cancer and concluded 
that there was CTC heterogeneity in signaling 
pathways that could contribute to treatment failure 
[19]. Pailler et al. investigated ALK-copy number gains 
(CNG) in individual CTCs by filter-adapted fluores-
cent in situ hybridization (FA-FISH) and reported a 
significant association between the dynamic evolution 
of the numbers of ALK-CNG and progression-free 
survival (PFS) in NSCLC patients treated with 
crizotinib, an ALK/ROS1 inhibitor [20]. Paolillo et al. 
found ESR1 mutations in single CTCs from metastatic 
breast cancer patients associated with endocrine 
therapy resistance [21]. As mentioned above, the 
tumor cell component is not the only source of 
heterogeneity. TME elements present high variability 
that can be assessed by single-cell analysis. Tirosh et 
al. presented an extensive study of the heterogeneity 
associated with the components that shape the 
melanoma micro-environment, assessed by single-cell 
RNA-seq. The authors discovered different micro- 
environments associated with distinct malignant cell 
profiles that could be used as prognostic markers [22].  
CTC cluster enrich CTC heterogeneity and have 
increased metastatic potential  
In addition to single CTCs detectable into the 
bloodstream, CTCs can be observed in clusters 
composed by cancer cells and/or in association with 
non-malignant cells. Recent findings suggest that CTC 
clusters may have a greater contribution to the 
metastatic process for mechanical and immune 
features. Indeed, Au et al. demonstrated that cluster 
CTCs are able to reorganize into single-file chain-like 
geometries in a rapid and reversible manner with 
reduced hydrodynamic resistance. Consequently, the 
progression of cluster CTCs through capillaries is 
slowed down and cancer cell clusters can traverse 
easily thin constrictions for extravasation and 
migration into distant organs [23-25]. CTC clusters are 
rare compared to single CTCs, do not come from 
intravascular aggregations and arise from oligoclonal 
cancer cell groupings (called homotypic CTC clusters) 
reinforcing the CTC heterogeneity [23-25]. 
Heterotypic CTC clusters have been also observed in 
patient samples. In that cases, CTC clusters are not 
only composed by tumor cell clones but are associated 
with tissue-derived macrophages [23-25], fibroblasts 
[23-25] or neutrophils [23-25]. Non-malignant cells 
escorting CTCs may strengthen the biomechanical 
properties of CTC clusters and may improve their 
survival. Very recently, Szczerba et al. demonstrated 
that the association between neutrophils and CTCs 
drove cell cycle progression within blood and 
increased the metastatic potential of CTCs in breast 
cancer patients [23-25].  
 However, heterotypic CTC clusters have never 
been associated with circulating lymphocytes. What 
could be the relationship between T lymphocytes and 
CTCs? A close relationship between immune cells and 
cancer cells has been described through the immune 
checkpoints [23-25].  Cancer cells can express 
programmed death-ligand (PDL-1) which binds to 
PD-1 and/or B7/1 expressed at the cell surface of T 
lymphocytes. This binding results in the inhibition of 
downstream signaling and in the decrease of T cell 
proliferation and an increase of their apoptosis. 
Recently, Mishra et al. compared the dialog between 
immune cells and CTCs isolated from non-metastatic 
and metastatic cell lines inoculated in syngeneic 
immune-competent mice [23-25]. In this model, the 
metastatic cell line exhibited a significant highrer 
expression of PDL-1 compared to the non-metastatic 
cell line and inoculation of activated immune cells 
had no impact on CTCs established from metastatic 
cell line in contrast to CTCs produced from 
non-metastatic cell line. PDL-1 was found to correlate 
with histological tumor grading and is frequently 
expressed by CTCs [23-25]. Since PDL-1 is a molecular 
regulator of regulatory T lymphocytes, a CTC 
immune escape mediated by PDL-1 can be 
hypothesized [23-25]. In such context, T lymphocytes 
may indirectly contribute to the tumor CTC 
heterogeneity by selecting specific dominant cancer 
cell clones that escape to the immune surveillance and 
lead to the release of specific CTCs into the 
bloodstream. To illustrate this purpose, Sun et al. 
studied a series of non-small cell lung cancer patients 
[23-25]. They observed that the number of CTCs were 
positively associated with the metastatic process and 
negatively associated with the level of circulating T 
lymphocytes. CTC cluster thanks the interactions 
between cancer cells and non-malignant cells 
contribute to the CTC survival, proliferation, immune 
escape and drug-resistance [23-25].   
Brief overview of the most significant 
breakthrough technologies for deciphering 
single-cell characteristics  
CTCs are rare cell events in blood with a 
frequency of around one tumor cell for 106-108 normal 
blood cells. Consequently, before single CTC analysis 
can take place, the first step is to enrich and isolate 
CTCs. Multiple technologies have been described to 
do this in individual CTCs, based on the different 
properties that distinguish them from surrounding 
normal hematopoietic cells, including biological 
properties (cell surface protein expression, viability, 





invasive capacity) and physical properties (size, 
density, electric charges, deformability) reviewed 
previously [23-25] (Figure 4A). Once single cells have 
been isolated, downstream analyses can be performed 
depending on the molecular components assessed: 
DNA, RNA or protein (Figure 4B). 
Single-cell DNA analysis 
Studying genetic variability in single cells has 
stimulated the development of several high 
throughput sensitive methods for detecting large 
patterns of mutations including target-specific 
amplification using PCR, as a means of querying 
specific loci of interest [26], and the next generation of 
sequencing approaches: whole exome sequencing 
(WES), [27] and whole genome sequencing (WGS) [28] 
to obtain information regarding the complete exome 
and genome respectively. As the amount of DNA that 
can be extracted from a single CTC is limited, an 
initial step involving whole genome amplification 
(WGA) is required. Depending on the downstream 
application, the WGA method selected can differ. 
Interestingly, recent studies compared different WGA 
methods and revealed that that multiple displacement 
amplification (MDA) methods are better suited for 
single nucleotide polymorphism (SNP) detection, 
while PCR-based methods are the better option for 
copy number variant (CNV) detection [29]. The 
authors suggested that AMPLI1 or MALBAC should 
be used in favor of the REPLi-G or PicoPlex kits when 
high target coverage is required [30]. They also found 
higher sensitivity of DOPlify and Picoseq for 
detecting 100% of CNVs than Ampli-1 and REPLI-g 
[31]. After genome amplification, the type of genomic 
investigation must be defined according to the 
objective of the study. For instance, Polzer et al. used a 
qPCR assay to analyze the variability of HER2 and 
PIK3CA in breast cancer single CTCs. Their findings 
demonstrated that assessing the heterogeneity for 
these two markers may uncover tumor evolution 
mechanisms useful for personalized therapy decisions 
[32]. In another study, Janiszewska et al. assessed 
single-nucleotide PIK3CA mutations and HER2 copy 
number alterations in single cells in formalin-fixed 
paraffin-embedded breast tumor samples using the 
STAR-FISH (specific-to-allele PCR–FISH) methodol-
ogy. This analysis proved to be useful for predicting 
clinical outcomes in breast cancer patients subjected 
to neo-adjuvant chemotherapy followed by adjuvant 
therapy with trastuzumab [33].  
 
 
Figure 4. Recent technological approaches used for isolating and characterising circulating tumor cells. A. Isolation of single CTCs is based on a two 
steps method including a pre-enrichment step followed by an isolation approach. All of these methods are related to the physicochemical or biological properties of 
CTCs. B. Single CTCs can be characterized by omic methods at the DNA, RNA and protein levels. 





In the last few years, there has been a significant 
increase in the number of studies that use next 
generation sequence approaches for unraveling single 
cell heterogeneity. The study performed by Li et al. 
identified 4 new driver mutations in renal cell carcin-
oma stem cells using WES that constitute important 
prognostic factors and therapeutic targets [34]. Liu et 
al. combined multi-region WES and single-cell WGS 
to examine the intra-tumor heterogeneity of rectal 
tumors. Their results suggest a specific architecture 
for each tumor related to different diagnoses, 
prognoses and drug responses [35]. Sequencing single 
CTC genomes and exomes provides considerable 
amounts of information, but also faces several 
technical challenges, in addition to difficulties with 
CTC capture [23]. The key limitations of single-cell 
sequencing using WGA are low coverage of the 
human genome and the consistency of the coverage 
between single cells [36]. This issue could be solved 
by third-generation sequencing technologies, such as 
the Pacific Bioscience system [37] and Nanopore 
sequencing [38]. The second challenge is data 
analysis, as currently the bioinformatics tools used for 
single-cell sequencing were initially developed and 
adapted for bulk cell sequencing. New computational 
and statistical methods have been developed to meet 
the requirements of single-cell analysis to reduce 
these biases and address biological and clinical 
questions more accurately [39-41]. 
Single-cell epigenetic analysis 
Robust technologies have been developed for 
mapping epigenetic marks in single cells. Bisulfite 
conversion followed by sequencing (BS-seq) is 
considered the gold-standard method for single base 
resolution and absolute quantification of DNA 
methylation levels [39-41]. Farlik et al. described a 
whole-genome bisulfite sequencing (WGBS) assay 
that makes it possible to analyze heterogeneous DNA 
methylation patterns in single cells (scWGBS) and 
compared it with the other two methods: single-cell 
reduced representation bisulfite sequencing (scRRBS) 
and single-cell post-bisulfite adaptor tagging 
(scPBAT) [42]. The authors concluded that scWGBS is 
the method of choice for analyzing large numbers of 
single cells at low sequencing coverage, scRRBS is 
useful for comparing CpG islands across single cells, 
and scPBAT is best suited for deep sequencing of 
single cells with maximum coverage [43]. For 
mapping histone marks at the single cell level, 
chromatin immunoprecipitation followed by sequen-
cing (ChIP-seq) has recently been implemented. 
Rotem et al. used this methodology to investigate the 
cell-to-cell variability of different types of regulatory 
elements and they confirmed its suitability for 
revealing aspects of epigenetic heterogeneity not 
captured by transcriptional analysis alone [44]. To 
assess the spatial organization of chromosomes, Kind 
et al. successfully modified the DamID method [45]. 
The heterogeneity of chromatin structure in single 
cells can be monitored by assay for transposase- 
accessible chromatin using sequencing (ATAC-seq) 
[46] and DNase I hypersensitive site sequencing 
(DNase-seq) [47]. Nowadays, it is also possible to 
assess variability in the 3D structure of chromosomes 
at the single cell level using a HiC-based method [48]. 
Other methodologies that have been developed to 
analyze epigenetic changes in bulk samples can 
potentially be adapted to single cell analysis [49]. 
Despite the fact that analyzing epigenetic state in 
CTCs is still in its infancy, various studies have 
already been published in the field. Pixberg et al. 
analyzed the epigenetic status of the genes associated 
with epithelial mesenchymal transition (EMT) in 
individual breast cancer CTCs, and explored potential 
intra- and inter-patient heterogeneity using the aga-
rose-embedded bisulfite sequencing (AEBS) protocol. 
They found heterogeneous methylation patterns in 
CTCs with clear infrequent hypermethylation at key 
promoters of the inhibitor genes of the EMT, suggest-
ing that both epithelial and mesenchymal CTCs can 
contribute equally to the metastatic process [50]. 
Single-cell RNA analysis 
Single-cell RNA sequencing (scRNAs) is the 
method selected if the aim of the study is to explore 
transcriptome heterogeneity [51]. Interestingly, Zieg-
enhain et al. performed a comparative analysis of the 
most prominent scRNA-seq methods and identified 
Drop-seq as the best method for analyzing the 
transcriptome of large numbers of cells with low 
sequencing depth, SCRB-seq and MARS-seq are 
preferable for the transcriptome of fewer cells, and 
Smart-seq2 would be the appropriate method of 
choice when annotating the transcriptome of very 
small quantities of cells [52]. All the data generated 
after scRNAs should be processed to avoid 
false-positives due to nonlinear amplification, 
false-negative allelic drop-out due to amplification 
bias, non-uniform coverage, and noise that arises 
during single-cell transcript amplification. Specific 
computational models have been specifically 
developed to address these issues [53]. 
Numerous studies show extensive use of 
scRNAs for unraveling CTC heterogeneity. Patel et al. 
reported the heterogeneity of single glioblastoma 
CTCs and the existence of high variability in signaling 
molecules relevant to the targeted therapy, a wide 
spectrum of stemness and differentiation states, 
variable proliferative capacity and expression of 





quiescence markers, all of which were related to the 
success or failure of therapeutic strategies [54]. Chung 
et al. used scRNA to characterize heterogeneity in 
tumor cells and TME components (mainly immune 
cells) in breast cancer. The authors identified various 
signatures in both compartments related to tumor 
development and the response to cancer therapy [55]. 
Despite the multiple advantages conferred by single- 
cell RNAseq, it also presents certain limitations that 
need to be resolved. The main ones are that RNA 
losses have to be kept to a minimum during cDNA 
conversion, and that the amplification should provide 
enough DNA for sequencing without too much 
quantitative bias or altering of the original picture of 
the cells’ transcriptomic profile. Moreover, scRNA-seq 
methods use an oligo-dT primer that specifically 
captures only polyadenylated RNA, avoiding the 
unwanted amplification of tRNA and rRNA. How-
ever, it represents a problem for the non-polyadenyl-
ated RNAs such as long non-coding RNA and 
microRNAs that have been shown to play important 
roles in cancer [56, 57]. Some commercial kits have 
been developed to overcome the poli(A) tail restric-
tion [58]. Another challenge is the low signal-to-noise 
ratio of single-cell RNA-seq technologies. It is thus 
important that cell isolation, library preparation, and 
other automated workflows be as standardized as 
possible to minimize any bias introduced by human 
error [59]. In this regard, Suzuki et al. proposed the 
use of standard cell lines in future quality controls 
[60]. Finally, many scRNA-seq analyses are still 
performed using methods originally developed for 
bulk RNA-seq even if their adaptability to single-cell 
transcriptomics is unclear [61]. As the reliability of the 
bioinformatic method directly determines the accur-
acy of the experimental results, it is important to 
develop bioinformatics tools specific to the analysis of 
single-cell RNA-seq data, such as the two very recent 
methods developed by Wu et al. [62] and Miao et al. 
[63]. 
Single-cell proteomic analysis 
Recent progress in microfluidic technologies and 
mass spectrometric approaches have led to new 
single-cell proteomics studies that could be performed 
with greater sensitivity and specificity. The micro- 
engraving technique, single-cell barcode chips 
(SCBCs) and single-cell Western blotting (scWB) are 
the microfluidic platforms providing the most advan-
ced capabilities [64]. The latest version of microfluidic 
image cytometry (MIC) makes it possible to analyze 
the heterogeneous expression of up to 90 proteins in 
each single cell [65]. Another technology is CyTOF, a 
mass cytometry platform that has been developed to 
assess phenotypic heterogeneity at the single cell 
level. It can simultaneously image the localization and 
modifications of 34 proteins (and potentially up to 
100) in each cell at subcellular resolution [66]. Sinkala 
et al. validated the clinical utility of proteomics in 
single cells by using scWB, and analyzed variability in 
metastatic breast cancer cells. They observed high 
heterogeneity in the expression of 8 key proteins 
related to breast cancer progression [67]. 
Conclusions and perspectives 
Repeatable, minimally-invasive and cost-effect-
ive approaches for real time assessment of relevant 
biomarkers and monitoring cancer therapies in the 
bloodstream have been developed to overcome the 
intrinsic limitations of primary tumor and metastasis 
biopsies. This field of investigation has been termed 
“liquid biopsy” and includes circulating tumor cells 
(CTCs), exosomes, circulating cell-free DNA (cfDNA), 
miRNAs and proteins. CTC characteristics can be 
considered to be a snapshot of overall tumor bulk 
(primary tumor and metastases). Compared to other 
liquid biopsies, CTCs are a little bit more laborious to 
obtain but can be analyzed at the DNA, RNA, and 
protein level, as well as with regard to their functional 
cellular characteristics as a means of providing 
information that relates to the whole cell [67, 68].  
Pooling the cells might provide different results 
and could mask clinically relevant rare mutations [18]. 
A major question emerges regarding the number of 
CTCs that need to be analyzed in order to capture the 
overall profile of the dominant disease driving the 
(sub)clones in a patient suffering from widespread 
metastatic disease. Gao et al. conducted a study on this 
subject and concluded that around 20-40 single cells 
are required to detect the main subclones with 95% 
power [69]. Despite promising results, showing a high 
concordance between paired CTCs and primary 
tumors or metastatic sites [15, 70], many other studies 
found discordant results between the mutational sta-
tus of CTCs and those of the corresponding primary 
tissue or metastasis [71-73]. Like tumor tissues, CTCs 
are in fact heterogeneous in all the cancer types 
analyzed [57,60, 131-143] (Table 1). Very recently, Sun 
et al. demonstrated the existence of specific CTC 
territories, marking the spatial heterogeneity of CTCs. 
These authors compared the EMT status of CTCs 
isolated from various vascular territories and 
observed surprisingly high heterogeneity depending 
on their location [138] and hypothesized that spatial 
CTC heterogeneity could impact both the recurrence 
of the disease and the metastatic process. This could 
be explained by the fact that CTCs reflect the dynamic 
evolution of the advanced stages of cancer more 
closely than the primary tumor (temporal hetero-
geneity) [18].  





Table 1. Recent studies analyzing the heterogeneity of circulating tumor cells (CTCs) at the single cell level. 
Analytical methods Isolation methods  Number of 
patients 





44 Analysis of KRAS and BRAF heterogeneity analyzed in CTCs can 
predict outcomes of anti‐EGFR therapy in colorectal cancer patients.  
[54] 
Foundation One™ CellSearch followed by 
single-cell isolation by DEPArray 
Markers used : EpCAM+/-, 
CD45-, DAPI 
32 CTC analysis can be used to identify targetable mutations, and as a 
biomarker to reveal the sensitivity to therapy of different breast cancer 
cell populations  
[55] 
PI3KCA Sanger sequencing  CellSearch followed by 
single-cell isolation by DEPArray 
Markers used : EpCAM+/-, 
CD45-, DAPI 
39 Detection of variability in PIK3CA gene mutational status in single 
CTCs isolated from breast cancer patients. PIK3CA mutations have 
prognostic significance and are potentially predictive for response to 
agents targeting the PI3K pathway 
[56] 
Filter-adapted-fluorescence 
in situ hybridization 
(FA-FISH) 
Filtration, Isolation by size of 
epithelial tumor cells (ISET) 
8 Heterogeneity of ROS1-gene abnormalities in CTCs from non-small 






No CTC isolation, detection of 
CTCs in blood samples 
10 Detection of cell heterogeneity in CTC drug-resistant clones with 
potential clinical value for treatment decisions (melanoma)                                                                  
[58] 
Next Generation Sequencing 
(NGS) 
CellSearch followed by 
single-cell isolation by DEPArray 
Markers used : EpCAM+/-, 
CD45-, DAPI 
4 High intra-tumor heterogeneity in breast single CTCs in genes related 
to therapeutic response. This can be used to assess the clonal 
evolution of metastatic breast cancer and further therapeutic 





Markers used : EpCAM+/-, 
CDH11+/-, CD45-  
22  Complex inter-tumor and intra-tumor heterogeneity in drug 
resistance mechanisms of analyzed prostate single CTCs relates to 
anti-androgen therapy failure. 
[62] 
FA-FISH Enrichment by ISET, 
enumeration by CellSearch  
Marker used: EpCAM+/-, CD45-  
18 Inter-tumor heterogeneity in CTC numbers with ALK-copy number 
gains has significant association with crizotinib efficacy and 
progression-free survival (PFS) in non-small cell lung carcinoma. 
[63] 
Sanger sequencing CellSearch  
Marker used: EpCAM+/-, CD45- 
30 Clonal heterogeneity analysis in single CTCs from metastatic breast 
cancer patients revealed early ESR1 mutations associated with 
endocrine therapy resistance. This can be used to predict which 
patients will benefit from a given therapy. 
[64] 
RNA-Seq Flow cytometry: CD45- 19 Detection of intra- and inter-individual heterogeneity in melanoma 
cells and tumor micro-environment components linked to resistance 
to targeted therapies.  
[65] 
 
 EMT biomarkers (e.g. TWIST1, SNAI1/2, 
N-cadherin, vimentin) are differentially expressed in 
CTCs [144-146]. EMT was shown to enhance 
metastatic properties of tumor cells. Markiewicz et al. 
analyzed the link between the detection of breast 
cancer CTCs with a mesenchymal phenotype and 
EMT status of primary tumors [147].  In their series, 
mesenchymal phenotype of CTCs was more frequent 
in primary tumors with E-cadherin loss compared to 
those with normal E-cadherin expression. However, 
EMT status of matched samples at different stages of 
dissemination was frequently discordant, especially 
for pairs associating CTCs. In more of 500 breast 
cancer patients, CTCs were detected in only 19% of 
blood samples [148]. These authors identified a subset 
of primary breast cancer patients with EMT (29%) and 
stem cell (14%) phenotype and they did find any 
correlation between these markers and other 
prognostic clinical markers. Similarly, it has been 
shown that around 30% of metastatic prostate cancer 
patients had no detectable EpCAM+ CTCs [149]. More 
recently, Lowes et al. studied the EMT process and 
CTC release in pre-clinical models of prostate cancer 
[150]. They confirmed that that the method used for 
isolating CTCs is crucial and that CellSearch®-based 
assay used in their study failed to detect around 
40-50% of CTCs with mesenchymal phenotype. 
Overall, these studies confirmed the high plasticity of 
cancer cells and demonstrated that the current 
methods used for detecting/isolating all subtypes of 
CTCs which undergo EMT are not efficient enough. 
Novel technological approaches are required to better 
follow the metastatic disease. 
 Nowadays, most of the studies published focus 
on revealing cell-to-cell differences at the DNA and 
RNA level. For overall understanding of single-cell 
heterogeneity, future studies should focus on the 
combination of different multi-omic assays on the 
same cell, such as the study performed by Hou et al. in 
which the authors used a single-cell triple omics 
sequencing technique called scTrio-seq which links 
the complex contribution of genomic and epigenomic 
heterogeneities to transcriptomic heterogeneity 
within a population of cells [151]. After conquering 
the barrier of multi-omics analysis for single cells, the 
final challenge will be temporal and spatial 
measurement of the molecular profile in a single cell. 
New technologies should not only solve the problem 
of the existing analysis methods which characterize 
only a snapshot profile of CTCs, but also provide 
real-time dynamics to measure patient status and then 
to follow the heterogeneity of the disease. The 
primary aspect of this new technology is in vivo 
monitoring and analysis of single CTCs, as has been 





shown in different studies [152, 153], but the high cost 
and lack of sensitivity prevent it from serving as a 
routine clinical test. In addition, future studies should 
also consider the importance of micro-environment 
and immunological elements in the heterogeneity 
state of cancer cells, as numerous emergent studies 
have demonstrated their consequences in tumor 
evolution and therapeutic response [7, 9, 10, 154]. In 
this regard, efforts must be made to clarify the 
complex interplay among cells within the tumor 
ecosystem and between functional states in space and 
time before its translational application [22] (Table B). 
Understanding tumor heterogeneity is of the utmost 
importance, as this phenomenon is associated with a 
decrease in diagnostic precision and is an obstacle for 
designing appropriate therapeutic strategies. 
Enumeration and molecular profiling of CTCs may be 
useful for a better patient stratification. High content 
analysis of CTCs can give a snapshot of the tumor 
heterogeneity at a given time and could allow to 
adapt therapeutic approach all along the treatment. 
Indeed, CTCs like all cancer cells are highly plastic 
and can modify their phenotype according the 
micro-environmental and therapeutic pressure. 
EGFR-mutated non-small lung cancer is a good 
illustration of cancer cell plasticity related to drug 
resistance [22]. EGFR-mutated NSCLC is a genetically 
heterogeneous disease with more than 200 distinct 
mutations. The identification of the most common 
L858R mutations-predict sensitivity to EGFR tyrosine 
kinase inhibitors. However, some patients become 
progressively resistant to the first line of tyrosine 
kinase inhibitor by developing new sets of mutations 
of EGFR illustrating again the plasticity of cancer 
cells.  CTCs collection is weakly invasive and would 
allow the follow up of EGFR mutation status in order 
to adapt the therapy “in real time” [155]. Genetic/ 
epigenetic/molecular profiling of CTCs open new era 
of personalized medicine. Unfortunately, the 
implementation of single CTCs in clinical practice is 
still limited because technologies are expensive, 
time-consuming and require standardization 
processes. Current protocols should be replaced by 
new ones that make it possible to obtain results in a 
short time and thus avoid any delay in treating the 
disease for cancer patients. 
Glossary 
Circulating tumor cells (CTCs): originate from 
the primary tumor or metastatic foci and at least some 
of them are able to invade the surrounding tissue, 
enter either the lymphatics or the bloodstream, 
survive in circulation, extravasate into a tissue and 
finally grow at the new site. 
Tumor micro-environment (TME): is the 
cellular environment in which the tumor exists, 
including surrounding blood vessels, immune cells, 
fibroblasts, bone marrow-derived inflammatory cells, 
lymphocytes, signaling molecules and the 
extracellular matrix. TME and tumors are 
closely-related and interact constantly. Cells in the 
micro-environment can affect the growth and 
evolution of tumor cells, while cancer cells can induce 
changes in the micro-environment by releasing 
extracellular signals, promoting tumor angiogenesis 
and inducing peripheral immune tolerance. 
Liquid biopsy: non-invasive test performed on 
blood samples for the capture and analysis of 
molecules originating from tumors such as CTCs, 
exosomes, miRNAs, proteins and circulating cell-free 
DNA. The main potential applications of this 
technique are: the screening and early detection of 
cancer; relapse-risk estimation; identification of 
therapeutic targets for precision medicine; and 
real-time monitoring of response to therapy and 
anticipation of emergent therapy resistance. 
Precision medicine: refers to the adjustment of 
medical treatment to the individual characteristics of 
each patient. It does not literally mean the creation of 
drugs or medical devices that are unique to a patient, 
but the ability to classify individuals into 
subpopulations that differ in their susceptibility to a 
particular disease, in the biology or prognosis of those 
diseases they may develop, or in their response to a 
specific treatment. Preventive or therapeutic 
interventions can then be concentrated on those who 
will benefit, sparing expense and side effects for those 
who will not. 
 
Table B. Precision of medicine: the future  
• Losing a significant amount of CTCs can be associated with 
subsequent misinterpretations of heterogeneity, and thus bad clinical 
decisions.   
• Future studies should focus on the combination of different 
multi-omics assays on the same cell to obtain a heterogeneity profile at 
different molecular levels. 
• Efforts should be made to implement in clinical practice real-time 
heterogeneity single CTC analysis to measure patient status at any 
time in the course of the disease.  
• Many studies have shown that TME plays an important role in tumor 
heterogeneity. Upcoming research studies assessing tumor 
heterogeneity thus need to include the analysis of different 
components in the TME.  
• It is mandatory to run clinical trials to clarify the clinical utility of CTC 
data. 
• The implementation of single cell heterogeneity analysis in clinical 
practice is a priority for improving precision medicine. Scientific and 
clinical communities should concentrate their efforts on solving the 
problem of high cost and time-consuming technologies. 
• A social debate is open for the near future regarding the difficulties 
many patients have with affording the high cost of getting diagnosed 
by precision medicine technologies. 
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